Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy

NCT00366002 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00366002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00366002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2006
Completion date
September 30, 2007
Enrollment
500 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder (oab)